Home Latest Articles
Latest Articles
  • Huiying ZHAO, Shengyu MA, Yun YANG, Xuexue LI
    World Clinical Drug. 2025, 46(2): 164-169.
    Objective

    To observe the efficacy of high-dose dexamethasone(DXM) combined with rafutrombopag in the treatment of newly diagnosed primary immunologic thrombocytopenic purpura(ITP).

    Methods

    A total of 80 newly diagnosed primary ITP patients in our hospital from June 2020 to June 2023 were enrolled and divided into control group(high-dose DXM) and study group(high-dose DXM+rafutrombopag) by district randomization method, with 40 cases in each group. Platelet count(PLT) levels, the distribution of T lymphocyte subsets, efficacy and the occurrence of adverse reactions were compared between the two groups before treatment and at D7, D14, D30 and D60 of treatment.

    Results

    At D7, D14, D30 and D60 of treatment, the PLT levels in both groups were higher than before(P<0.05), and the PLT levels of the study group were higher than those in the control group at D7, D14 and D30(P<0.05). After treatment, cluster of differentiation(CD)3+, CD4+, CD4+/CD8+, complement C3, complement C4 and interleukin(IL)-4 in both groups were increased compared with those before treatment(P<0.05), and the study group was higher than the control group(P<0.05). The levels of CD8+, IL-2, IL-10 and interferon in both groups were lower than before treatment(P<0.05), and the study group was lower than the control group(P<0.05). The total effective rate of the study group was higher than that of the control group(85.00% vs. 65.00%, P<0.05), the rate of DXM secondary administration(10.00% vs. 30.00%, P<0.05) and the incidence of adverse reactions(25.00% vs. 52.50%, P<0.05) were lower than those of the control group.

    Conclusion

    High-dose DXM combined with rafutrombopag in the treatment of newly diagnosed primary ITP can effectively up-regulate PLT level, improve the distribution of T lymphocyte subsets, improve efficacy, and reduce the rate of DXM secondary administration and the incidence of adverse reactions.

  • Haiyan TIAN, Lili WEI, Ruwei QIN
    World Clinical Drug. 2025, 46(2): 170-175.
    Objective

    To investigate the therapeutic effect of idebenone combined with dopamine on Parkinson's disease(PD) and its effects on serum neurocytokines and oxidative stress indexes.

    Methods

    A total of 130 PD patients in our hospital from June 2022 to December 2023 were selected and divided into observation group and control group according to simple ordering random method, with 65 cases in each group. On the basis of conventional treatment, the control group was treated with levodopa and benserazide hydrochloride tablets, and the observation group was treated with idebenone on the treatment regimen of the control group. The course of treatment of both groups was 3 months. The clinical efficacy, the unified PD rating scale(MDS-UPDRS)Ⅲ, non-motor symptoms scale(NMSS), mini mental status examination(MMSE) score, and nerve growth factor(NGF), brain-derived neurotrophic factor(BDNF), malondialdehyde(MDA), superoxide dismutase(SOD), glutathione peroxidase(GSH-Px) and catalase(CAT) were compared between the two groups.

    Results

    The overall response rate of observation group was higher than that of control group (84.62% vs. 67.69%, P<0.05). The MDS-UPDRS III, NMSS score and serum MDA level in the observation group were lower than those in the control group(P<0.05). The MMSE score, serum NGF, BDNF, SOD, GSH-Px and CAT levels in observation group were higher than those in control group(P<0.05).

    Conclusion

    Idebenone combined with dopamine is effective in the treatment of PD, which can improve the symptoms and cognitive function of patients, and its mechanism may be related to the regulation of serum neurocytokines and oxidative stress response.

  • Saiting SHI, Jianmei YANG, ge ZHANG, Xiangqian XU, Xiaoyu XU
    World Clinical Drug. 2025, 46(2): 176-183.
    Objective

    To observe the effect of medicated cupping on stable chronic obstructive pulmonary disease(COPD) patients with lung and kidney deficiency syndrome.

    Methods

    A total of 66 patients with stable COPD in the outpatient and ward of Respiratory Department of our hospital from January 2022 to January 2024 were selected and divided into experimental group and control group according to the simple sorting random method, with 33 cases in each group. The experimental group was treated with Sanziqi Bai decoction combined with cupping treatment at the acupoints of Dazhui, Dingchuan, Gaomang, Feishu, Shenshu and Zusanli, while the control group was given simple cupping treatment on Mondays and Thursdays, twice a week for 8 weeks. This study mainly observed the changes of forced expiratory volume in one second(FEV1)/forced vital capacity(FVC). The secondary outcome measures included peak expiratory flow, percentage of predicted value of FEV1 (FEV1%), percentage of predicted value of FVC(FVC%), and C-reactive protein, tumor necrosis factor(TNF)-α, COPD assessment test(CAT), 6-minute walk test (6MWT) and the change of traditional Chinese medicine(TCM) syndrome score.

    Results

    After treatment, the FEV1/FVC of the patients in the experimental group was higher than that of the control group, and the TCM syndrome score was lower(P<0.05). Compared with before treatment, the FEV1%, FVC% and 6MWT of experimental group were increased, while TNF-α, CAT score and TCM syndrome score were decreased(P<0.05), the therapeutic effect of experimental group was better than that of control group(P<0.05).

    Conclusions

    Medicated cupping is effective in treating stable COPD patients with lung-kidney deficiency, effectively improving lung function, TCM syndrome score, reducing inflammation and improving quality of life.

  • Yanci LI, Jianfang LIU, Yanping ZHANG, Xiaojiao WANG, Xia ZHENG, Yao MENG
    World Clinical Drug. 2025, 46(2): 184-187.
  • Bing HU, Lili GONG, Liang PENG, Haojun ZHANG, Hankun HU, Lihong LIU
    World Clinical Drug. 2025, 46(2): 188-195.

    The BXD recombinant inbred mouse strains, developed through the hybridization of female C57BL/6J and male DBA/2J mice, followed by over 20 generations of brother-sister matings, represent the largest and most genetically characterized group of recombinant inbred strain populations of mammals globally, with over 150 strains. These mice exhibit significant genetic diversity and extensive phenotypic variation, alongside a wealth of genotype, phenotype, and omics data. These characteristics make BXD mice a valuable resource for studying complex traits and diseases, which can be used for the construction of disease models, the study of disease mechanisms, drug target discovery, and preclinical drug evaluation. The application of BXD mice is crucial in advancing biomedical research, promoting disease prevention and treatment, and achieving precision medicine. With the deepening of research, BXD mice are poised to play a greater role across various fields.

  • Xingyue FAN, Yaqin HOU, Xu JIA
    World Clinical Drug. 2025, 46(2): 196-202.

    Intracranial infections caused by multidrug-resistant Gram-negative bacteria is a difficult problem in clinical treatment. Tigecycline, a novel antibiotic, has demonstrated potential against multidrug-resistant Gram-negative bacteria and has become an important option for treating intracranial infections. This article reviewed the research progress of tigecycline in treating intracranial infections, including its antimicrobial mechanism, pharmacokinetic characteristics, and therapeutic efficacy. It also pointed out that the safety of tigecycline treatment needed further verification. It was recommended to minimize the potential risks of tigecycline in the treatment for intracranial infections, balance the efficacy and safety, and achieve optimal treatment through individualized treatment plans, combination therapy, pharmaceutical monitoring and evaluation in clinical practice.

  • Luyao LI, Sha WANG, Xiangdong YANG
    World Clinical Drug. 2025, 46(2): 203-206.

    Autoimmune disease(AID) is a class of diseases characterized by excessive inflammatory response to autoantigens, B lymphocytes are the core of the pathogenesis of AID, and cluster of differentiation(CD)20 monoclonal antibodies targeting at B lymphocytes depletion are widely used in the treatment of AID. Obinutuzumab, a type Ⅱhumanized anti-CD20 monoclonal antibody, can significantly reduce the number of B lymphocytes and inhibit the production of autoantibodies, and can be used to treat AID. This article reviewed the application progress of obinutuzumab in AID, aiming to provide some reference for clinical use.

  • Wenxin XU, Qiuyue GUO, Xu HAN, Qingguang CHEN, Hao LU, Mengjie CAI
    World Clinical Drug. 2025, 46(2): 207-210.

    Pancreatic fat deposition can impair the function of islet β cells and is closely related to the occurrence and development of type 2 diabetes mellitus(T2DM). Therefore, reducing pancreatic fat deposition is an important step to promote the remission of T2DM. Traditional Chinese medicine(TCM) believes that pancreatic fat deposition is related to the abnormal function of spleen transportation and metabolism, and Chinese herbal compounds with the effect of invigorating spleen and qi can reduce pancreatic fat deposition. This article systematically reviewed the relationship between pancreatic fat deposition and the pathogenesis of T2DM, and the improvement effect of TCM on it, in order to provide new directions and ideas for the treatment of T2DM with TCM and western medicine treatment.

  • Sainan ZHANG, Niansong WANG, Wei ZHANG
    World Clinical Drug. 2025, 46(1): 1-7.

    The development of novel biologics provides a new therapeutic strategy for immune-related kidney diseases. Novel biologics such as anti-leukocyte differentiation antigen 20 monoclonal antibody, B lymphocyte stimulator/a proliferation-inducing ligand-targeting drugs, and complement inhibitors provide more precise treatment for immune-related kidney diseases by targeting specific molecules or receptors. However, further studies are needed in terms of therapeutic efficacy, safety, optimal dosage and applicability in different kidney diseases. This article reviewed the application progress of various novel biologics in immune-related kidney diseases, and aimed to discuss their therapeutic potential, existing evidence and future research direction.

  • Wei WANG, Ying FAN, Niansong WANG
    World Clinical Drug. 2025, 46(1): 8-13.

    Glucagon-like peptide-1 receptor agonist(GLP-1RA) has been widely used in the treatment of patients with type 2 diabetes mellitus. GLP-1RA can also help improve renal outcomes in patients with diabetic nephropathy(DN).GLP-1RA plays a renal protective role by inhibiting inflammatory response, reducing oxidative stress, alleviating damage induced by advanced glycosylation end products and improving metabolic abnormalities, and has great potential in preventing and slowing down the occurrence and development of DN. This article reviewed the clinical evidence and mechanism of GLP-1RA in DN, so as to provide reference for clinical use.

News